# FDA Removes 12 Peptides from Category 2 Restrictions: What Changed in April 2026
In April 2026, the FDA announced it would remove 12 popular peptides from Category 2 restrictions β including some of the most widely used compounds in biohacking, regenerative medicine, and peptide therapy circles.
The move represents the most significant regulatory shift in the peptide space in years. Compounds affected include BPC-157, TB-500, MOTS-C, GHK-Cu, and Semax β each with distinct clinical profiles and dedicated user bases.
This article breaks down what Category 2 actually means, which peptides were removed, what the July 2026 meeting signals, and what this means practically for people using or prescribing peptide therapies.
What Are Category 2 Peptides?
The FDA's bulk substance framework for compounding pharmacies β established under the 2013 Drug Quality and Security Act β divides peptides into three categories relevant to 503A/503B compounding:
- Category 1: Affirmed for compounding. Pharmacies can prepare these without additional exemptions.
- Category 2: Subject to review or restriction. Compounding is restricted or requires additional oversight.
- Negative List: Prohibited from compounding entirely.
- BPC-157 (Body Protection Compound-157)
- TB-500 (Thymosin Beta-4)
- MOTS-C (Mitochondrial-derived Peptide)
- GHK-Cu (Copper-binding Tripeptide)
- Semax (Synthetic ACTH analog)
- Selank (Synthetic tuftsin analog)
- DSIP (Delta Sleep-Inducing Peptide)
- Epithalon (Epithelial Peptide)
- Kotan (Derivative of Selank)
- CG-250 (Radiolabeled somatostatin analog, limited clinical use)
- N-Acetyl Semax (Semax variant)
- Dihexa (Angiotensin IV analog, nootropic applications)
- These peptides are FDA-approved drugs
- Compounding pharmacies are affirmatively cleared to manufacture them at scale
- Insurance will cover them
- They're legal in all contexts for all uses
- Bulk substance affirmation criteria: What evidence threshold qualifies a peptide for Category 1?
- Safety data review: What adverse event reporting requirements apply?
- compounding pharmacy standards: What QA/QC conditions should govern large-scale compounding?
- Individual patient prescribing: How physician discretion interacts with compounding rules
- Legal clarity: Pharmacies no longer need to fear FDA enforcement action specifically for compounding these 12 peptides
- Inventory restoration: Pharmacies that removed these peptides from their formularies due to legal risk can restore them
- Quality improvements: As legitimate compounding channels reopen, the quality gap between regulated and gray-market sources should narrow
- Pricing normalization: As multiple compounding pharmacies compete, excessive premiums for "research use only" labeling should decline
- More pharmacy options: Physicians prescribing BPC-157, MOTS-C, or other affected peptides should find more pharmacies willing to fill the prescription
- Better quality control: Legitimate compounding pharmacies must meet sterility, potency, and endotoxin testing standards that gray-market sources typically don't
- Lower costs: Competition among compounding pharmacies typically drives prices down versus single-source gray-market procurement
- Telehealth access: Peptide-prescribing telehealth services that stopped offering these compounds due to pharmacy access problems may resume
- Will any of the 12 peptides receive formal Category 1 designation?
- What safety data or adverse event reporting requirements will the FDA propose?
- Will the FDA engage with the growing body of human clinical data for BPC-157 specifically?
- How quickly will compounding pharmacies update their formularies in response?
For years, many widely-used peptides sat in Category 2 not because of safety failures, but because the FDA's review process lagged behind clinical demand and real-world use. BPC-157 is the canonical example β studied since the 1990s, used by thousands of physicians, yet never formally affirmed for compounding.
Category 2 status created a gray zone. Pharmacies that compounded these peptides operated under legal uncertainty. Some stopped. Others charged premiums for "research use only" labeling. Patients and doctors lost reliable access to quality-controlled sources.
The April 2026 Announcement: What It Says
The FDA's April 2026 announcement removed 12 peptides from Category 2 status. The full list includes:
The announcement did not move these peptides to Category 1 β a distinction that matters. Instead, the FDA removed enforcement priority for these compounds, effectively treating them as neither affirmed nor prohibited in the bulk substance framework.
What This Is Not: FDA Approval
A critical distinction: removal from Category 2 enforcement priority is not the same as FDA approval or Category 1 affirmation.
This announcement means the FDA is no longer actively treating these 12 peptides as compounding compliance targets. It does not mean:
What it does mean: the chilling effect on compounding pharmacies largely disappears. Pharmacies that were hesitant to compound these peptides due to enforcement risk now have clearer ground to operate. Physicians prescribing them face less institutionalι»ε.
The July 2026 Meeting: Approval Pathways Ahead
The FDA has scheduled a July 2026 public meeting to explore formal approval pathways for these and similar peptides. This meeting is significant because it signals the agency is willing to engage with the clinical and safety data rather than continue the enforcement-priority posture.
Topics expected to be discussed at the July meeting:
The July 2026 meeting does not guarantee that all 12 peptides will receive Category 1 designation. But it represents the most substantive regulatory engagement with peptide compounding since the 2023 FDA crackdown.
Peptide-by-Peptide: What the Removal Means
BPC-157
BPC-157 has the most at stake in this regulatory shift. Studied since the early 1990s for gut healing, tendon repair, and systemic recovery, BPC-157 has never been placed on the formal Category 1 list β yet it has one of the most extensive safety records in the peptide literature.
Removal from Category 2 enforcement means compounding pharmacies can resume offering BPC-157 preparations with less legal exposure. Physicians prescribing BPC-157 for gut disorders, musculoskeletal injuries, and post-surgical recovery can expect more reliable pharmacy access.
The July 2026 pathway discussion could move BPC-157 to Category 1 β which would affirmatively clear it for compounding rather than just removing enforcement priority.
TB-500
TB-500 (Thymosin Beta-4) has been used primarily for wound healing, anti-inflammatory applications, and some athletic injury recovery. It shares a similar regulatory history to BPC-157 β widely used, extensively researched in animal models, but never formally affirmed for compounding.
The April 2026 removal has the same practical effect for TB-500 as for BPC-157: compounding pharmacies face less enforcement risk, and physician-prescribed TB-500 should become more consistently available.
MOTS-C
MOTS-C is a mitochondrial-derived peptide that has garnered significant attention for its metabolic effects β particularly glucose regulation and insulin sensitivity. Research from 2022β2025 has expanded its profile to include potential anti-aging applications via mitochondrial function modulation.
MOTS-C's regulatory position has been complicated by its relatively recent emergence in clinical literature. The FDA's April 2026 removal from Category 2 enforcement reflects a broader willingness to revisit newer peptides that were swept into the 2023 crackdown without individual review.
GHK-Cu
GHK-Cu (Copper Tripeptide) is one of the most well-studied peptides for skin health, wound healing, and anti-aging applications. It has human clinical data supporting collagen stimulation, antioxidant activity, and gene expression modulation.
GHK-Cu's regulatory position has always been somewhat unusual β it is a naturally occurring peptide present in human tissue, making the "bulk substance" framework a poor fit. The April 2026 removal from Category 2 enforcement acknowledges this and reflects a more scientifically accurate treatment of GHK-Cu.
Semax and Selank
Semax and Selank are Russian-developed peptides with nootropic and anxiolytic applications. Both have been used clinically in their countries of origin for decades. Semax has shown promise in cognitive enhancement and stroke recovery; Selank has been studied for anxiety modulation and stress adaptation.
Both peptides were caught in the Category 2 enforcement framework despite decades of clinical use abroad and growing U.S. physician interest. Their removal from active enforcement reflects the FDA's acknowledgment that the regulatory apparatus didn't fit their safety and usage profiles.
What This Means for Compounding Pharmacies
For compounding pharmacies, the practical implications are significant:
503B outsourcing facilities β which compound for hospitals and clinics β will likely move faster than individual 503A pharmacies due to their larger scale and regulatory compliance infrastructure.
What This Means for Patients and Prescribers
For individuals using peptide therapies under physician supervision:
For those using peptides sourced from research chemical vendors: the gray market will likely shrink as legitimate compounding access improves. This is a net positive for safety and quality, but it also means those sources become comparatively less necessary.
What to Watch Going Forward
The July 2026 FDA meeting is the next major event to track. Key questions:
PeptIQ will continue monitoring the regulatory landscape and will report significant developments as they occur.
FAQ: FDA April 2026 Peptide Regulatory Shift
Q: Does the April 2026 announcement mean BPC-157 is now FDA-approved?
A: No. FDA approval requires a New Drug Application (NDA) with clinical trial data submitted for review. This announcement only removes enforcement priority for 12 peptides that were previously in Category 2 restriction. These peptides remain investigational.
Q: Can I now get BPC-157 from my local compounding pharmacy?
A: Possibly, depending on your pharmacy. The announcement removes enforcement risk, so pharmacies that previously declined to compound BPC-157 may now be willing. Call your pharmacy directly to ask about their current formulary and compounding policies.
Q: Are all 12 peptides now legal to compound?
A: They are no longer enforcement priorities, which means compounding pharmacies face reduced legal risk. They are not affirmatively cleared in the same way Category 1 peptides are. The practical effect is similar for most compounding pharmacies, but the legal distinction is real.
Q: Does this affect WADA's prohibition on BPC-157 in competitive sports?
A: No. The FDA announcement has no effect on sports anti-doping rules. WADA's prohibition on BPC-157 remains in place for competitive athletes regardless of FDA enforcement posture.
Q: What peptides were NOT affected by this announcement?
A: Several peptides remain in Category 2 or under enforcement scrutiny. Retatrutide, tirzepatide, and other approved or near-approval peptides have their own regulatory pathways. Always check current compounding pharmacy formularies and FDA guidance for specific compounds.
Q: Should I switch from gray-market sources to compounded peptides now?
A: If your physician is prescribing a peptide and your pharmacy can compound it, that's a meaningfully higher quality-control standard than research chemical vendors. The April 2026 announcement makes this transition more feasible for more people. Discuss with your prescribing physician.
---
Stay Ahead of Peptide Regulatory Changes
The regulatory landscape for peptides changes fast. What was restricted in 2023 is being reconsidered in 2026. Staying current matters β both for safety and for access.
PeptIQ monitors FDA filings, compounding pharmacy policy, and clinical research developments across the peptide space. Download the app to get research-backed guidance on peptide therapy, compounding access, and regulatory developments as they happen.
